Outlook Therapeutics CFO buys stock and warrants
Outlook Therapeutics, Inc. director and Chief Financial Officer Lawrence A. Kenyon reported open-market-style purchases tied to an underwritten public offering on August 14, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Outlook Therapeutics, Inc. director and Chief Financial Officer Lawrence A. Kenyon reported open-market-style purchases tied to an underwritten public offering on August 14, 2026. He acquired 101,010 shares of common stock plus accompanying warrants to purchase another 101,010 shares, for a combined public offering price of $0.99 per share and warrant. The warrants are immediately exercisable at $1.10 per share and expire on August 14, 2031. Following the stock purchase, he held 106,956 common shares directly.
Insider Trade Summary
Net Buyer: 202,020 shares
Net Buy
2 txns
Insider
KENYON LAWRENCE A
Role
Chief Financial Officer
Bought
202,020 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Warrants (right to buy) F2, F1 | 101,010 | -- | -- |
| Purchase | Common Stock F1 | 101,010 | -- | -- |
Holdings After Transaction:
Warrants (right to buy) — 101,010 contracts (Direct);
Common Stock — 106,956 shares (Direct)
Footnotes (2)
- F1. On August 14, 2026, the reporting person acquired 101,010 shares of common stock and accompanying warrants to purchase 101,010 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.
- F2. The warrants were exercisable immediately upon issuance and expire five years from the date of issuance, on August 14, 2031.
Key Figures
Common shares purchased: 101,010 shares
Warrants acquired: 101,010 warrants
Combined offering price: $0.99 per share and warrant
+4 more
7 metrics
Common shares purchased
101,010 shares
Shares of Outlook Therapeutics common stock acquired on August 14, 2026
Warrants acquired
101,010 warrants
Warrants to purchase common stock acquired in the same August 14, 2026 offering
Combined offering price
$0.99 per share and warrant
Public offering price per unit of one common share plus one accompanying warrant
Warrant exercise price
$1.10 per share
Exercise price of the warrants acquired on August 14, 2026
Warrant expiration date
August 14, 2031
Warrants are exercisable immediately and expire five years from issuance
Shares owned after transaction
106,956 shares
Direct common stock holdings reported following the August 14, 2026 purchase
Total net shares bought
202,020 securities
Sum of 101,010 common shares and 101,010 underlying warrant shares acquired
Key Terms
underwritten public offering, accompanying warrants, combined public offering price, exercise price, +1 more
5 terms
underwritten public offering financial
"the Issuer's underwritten public offering of shares of common stock"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
accompanying warrants financial
"shares of common stock and accompanying warrants to purchase 101,010 shares"
Securities called accompanying warrants are options issued together with another financing instrument—often bonds or preferred shares—that give the holder the right to buy common stock at a set price for a limited time. Think of them like detachable coupons included with a loan that can be redeemed later for stock; they matter to investors because they can dilute existing ownership if exercised and add potential upside tied to the issuer’s future share price.
combined public offering price financial
"for a combined public offering price of $0.99 per share of common stock"
exercise price financial
"The warrants were exercisable immediately upon issuance"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expire five years from the date of issuance, on August 14, 2031"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Outlook Therapeutics (OTLK) CFO Lawrence A. Kenyon buy on August 14, 2026?
Lawrence A. Kenyon acquired 101,010 shares of common stock and warrants for 101,010 shares in Outlook Therapeutics’ underwritten public offering on August 14, 2026, increasing both his stock and warrant positions.
At what price did the Outlook Therapeutics (OTLK) CFO participate in the offering?
Kenyon participated at a combined public offering price of $0.99 per share of common stock and accompanying warrant. This price covers each unit consisting of one share plus one warrant in the underwritten public offering.
What are the key terms of the Outlook Therapeutics (OTLK) warrants acquired by the CFO?
The acquired warrants are immediately exercisable at an exercise price of $1.10 per share and will expire on August 14, 2031, giving Kenyon the right to buy 101,010 common shares during that period.
Were the Outlook Therapeutics (OTLK) CFO’s August 14, 2026 transactions under a Rule 10b5-1 plan?
The filing indicates the Rule 10b5-1 checkbox as not selected, and the footnotes describe participation in an underwritten public offering, not trades executed under a pre-arranged Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
